ECSP21072994A - Inhibidores de la proteína tirosina fosfatasa - Google Patents

Inhibidores de la proteína tirosina fosfatasa

Info

Publication number
ECSP21072994A
ECSP21072994A ECSENADI202172994A ECDI202172994A ECSP21072994A EC SP21072994 A ECSP21072994 A EC SP21072994A EC SENADI202172994 A ECSENADI202172994 A EC SENADI202172994A EC DI202172994 A ECDI202172994 A EC DI202172994A EC SP21072994 A ECSP21072994 A EC SP21072994A
Authority
EC
Ecuador
Prior art keywords
protein tyrosine
tyrosine phosphatase
phosphatase inhibitors
tautomer
stereoisomer
Prior art date
Application number
ECSENADI202172994A
Other languages
English (en)
Inventor
Martha E Rodriguez
Christina E Wong
James F Blake
Adam W Cook
Jay Bradford Fell
Mark Joseph Chicarelli
Mark Laurence Boys
Yutong Jiang
Oren T Mcnulty
John P Fischer
Mohamed S A Elsayed
Macedonio J Mejia
Ronald Jay Hinklin
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of ECSP21072994A publication Critical patent/ECSP21072994A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos de la Fórmula I o un estereoisómero, tautómero, profármaco o sal aceptable desde el punto de vista farmacéutico de este, que son útiles para el tratamiento de enfermedades hiperproliferativas. Se divulgan métodos para usar los compuestos de la Fórmula I o un estereoisómero, tautómero, profármaco o sal aceptable desde el punto de vista farmacéutico de estos, para el diagnóstico in vitro, in situ e in vivo, la prevención o el tratamiento de dichos trastornos en células de mamífero, o las afecciones patológicas relacionadas.
ECSENADI202172994A 2019-04-02 2021-09-30 Inhibidores de la proteína tirosina fosfatasa ECSP21072994A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962828356P 2019-04-02 2019-04-02
US202062992558P 2020-03-20 2020-03-20

Publications (1)

Publication Number Publication Date
ECSP21072994A true ECSP21072994A (es) 2021-11-18

Family

ID=70277430

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202172994A ECSP21072994A (es) 2019-04-02 2021-09-30 Inhibidores de la proteína tirosina fosfatasa

Country Status (24)

Country Link
US (3) US11634417B2 (es)
EP (1) EP3947367A1 (es)
JP (2) JP7284830B2 (es)
KR (1) KR20210146389A (es)
CN (1) CN113874363A (es)
AU (1) AU2020251841A1 (es)
BR (1) BR112021018664A2 (es)
CA (1) CA3135555C (es)
CL (1) CL2021002542A1 (es)
CO (1) CO2021013030A2 (es)
CR (1) CR20210501A (es)
CU (1) CU20210080A7 (es)
DO (1) DOP2021000206A (es)
EC (1) ECSP21072994A (es)
GE (1) GEP20237561B (es)
IL (1) IL286462A (es)
MA (1) MA55511A (es)
MX (1) MX2021012122A (es)
PE (1) PE20220141A1 (es)
SG (1) SG11202110502PA (es)
TW (1) TWI766261B (es)
UY (1) UY38628A (es)
WO (1) WO2020201991A1 (es)
ZA (1) ZA202108443B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
JP2023541916A (ja) 2020-09-15 2023-10-04 レボリューション メディシンズ インコーポレイテッド がんの治療における、ｒａｓ阻害剤としてのインドール誘導体
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN117083285A (zh) * 2021-03-31 2023-11-17 南京明德新药研发有限公司 一系列含Se的吡嗪类化合物及其应用
MX2023011664A (es) 2021-04-01 2023-10-11 Array Biopharma Inc Forma cristalina de un inhibidor de shp2.
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
TW202244049A (zh) * 2021-05-12 2022-11-16 大陸商藥雅科技（上海）有限公司 Shp2磷酸酶抑制劑的製備及其應用
KR20230011245A (ko) 2021-07-09 2023-01-20 주식회사 카나프테라퓨틱스 Shp2 억제제 및 이의 용도
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023061263A1 (zh) * 2021-10-14 2023-04-20 北京泰德制药股份有限公司 Shp2抑制剂、包含其的药物组合物及其用途
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023180898A1 (en) 2022-03-23 2023-09-28 Array Biopharma Inc. Crystalline salt form of a shp2 inhibitor
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
WO2013056183A1 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them
WO2014036015A1 (en) 2012-08-27 2014-03-06 Array Biopharma Inc. Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
RU2643361C2 (ru) 2013-09-30 2018-02-01 Кореа Рисёч Инститьют Оф Кемикал Текнолоджи Новые производные триазолопиразина и их применение
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
EP3310771B1 (en) 2015-06-19 2020-07-22 Novartis AG Compounds and compositions for inhibiting the activity of shp2
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
EP3310774B1 (en) * 2015-06-19 2020-04-29 Novartis AG Compounds and compositions for inhibiting the activity of shp2
CN109475531B (zh) 2016-05-31 2021-08-17 得克萨斯州立大学董事会 Ptpn11的杂环抑制剂
US10858359B2 (en) 2016-06-07 2020-12-08 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic ring derivatives useful as SHP2 inhibitors
BR112018075663A2 (pt) 2016-06-14 2019-04-09 Novartis Ag compostos e composições para a inibição da atividade de shp2
CN109983001B (zh) * 2016-07-12 2023-04-04 锐新医药公司 作为变构shp2抑制剂的2,5-双取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
EP3515916B1 (en) 2016-09-22 2023-06-07 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW201819386A (zh) 2016-10-24 2018-06-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
TWI820013B (zh) 2017-01-23 2023-11-01 美商銳新醫藥公司 作為別構ｓｈｐ２抑制劑之雙環化合物
JP7240320B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としてのピリジン化合物
SG11201908820VA (en) * 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
KR20200051684A (ko) 2017-09-07 2020-05-13 레볼루션 메디슨즈, 인크. 암 치료를 위한 shp2 억제제 조성물 및 방법
US10435389B2 (en) 2017-09-11 2019-10-08 Krouzon Pharmaccuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
WO2019067843A1 (en) 2017-09-29 2019-04-04 Relay Therapeutics, Inc. PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2
EP3694848A1 (en) 2017-10-12 2020-08-19 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
TW201927791A (zh) 2017-12-15 2019-07-16 美商銳新醫藥公司 作為變構shp2抑制劑的多環化合物
WO2019152454A1 (en) 2018-01-30 2019-08-08 Research Development Foundation Shp2 inhibitors and methods of use thereof
EP3768680A1 (en) 2018-03-21 2021-01-27 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
RU2020133727A (ru) 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
MX2020009782A (es) 2018-03-21 2021-01-20 Relay Therapeutics Inc Inhibidores de la fosfatasa shp2 y métodos para su uso.
EP4356973A3 (en) 2018-08-10 2024-06-26 Navire Pharma, Inc. 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
US20210393623A1 (en) * 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
IL282179B1 (en) 2018-10-17 2024-06-01 Array Biopharma Inc Protein tyrosine phosphatase inhibitors

Also Published As

Publication number Publication date
JP2022527796A (ja) 2022-06-06
AU2020251841A1 (en) 2021-10-07
DOP2021000206A (es) 2021-11-21
CO2021013030A2 (es) 2021-10-20
BR112021018664A2 (pt) 2021-11-23
PE20220141A1 (es) 2022-01-27
JP7284830B2 (ja) 2023-05-31
US20220251083A1 (en) 2022-08-11
CA3135555A1 (en) 2020-10-08
KR20210146389A (ko) 2021-12-03
CL2021002542A1 (es) 2022-06-24
ZA202108443B (en) 2023-04-26
CA3135555C (en) 2023-09-19
US11884664B2 (en) 2024-01-30
UY38628A (es) 2020-10-30
JP2023078421A (ja) 2023-06-06
EP3947367A1 (en) 2022-02-09
CR20210501A (es) 2021-11-02
WO2020201991A1 (en) 2020-10-08
MA55511A (fr) 2022-02-09
US11634417B2 (en) 2023-04-25
TW202102490A (zh) 2021-01-16
SG11202110502PA (en) 2021-10-28
CU20210080A7 (es) 2022-05-11
US20200317665A1 (en) 2020-10-08
US20240124453A1 (en) 2024-04-18
GEP20237561B (en) 2023-10-25
MX2021012122A (es) 2021-11-03
IL286462A (en) 2021-10-31
TWI766261B (zh) 2022-06-01
CN113874363A (zh) 2021-12-31

Similar Documents

Publication Publication Date Title
ECSP21072994A (es) Inhibidores de la proteína tirosina fosfatasa
NI202100027A (es) Inhibidores de la proteína tirosina fosfatasa
BR112023001195A2 (pt) Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto
DOP2022000117A (es) Inhibidores de kras g12c
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
CY1120172T1 (el) Αναστολεις κινασων σερινης/θρεονινης
AR116604A1 (es) Inhibidores de kras g12c
BR112016015236A8 (pt) composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença.
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
ECSP10010510A (es) Compuestos del inhibidor de raf y métodos de uso de los mismos
ECSP10010507A (es) Pirazolo (3, 4-b) piridina inhibidores de raf
PA8779701A1 (es) Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
AR125425A1 (es) Inhibidores de proteina tirosina fosfatasa y sus metodos de uso
MX2016008449A (es) Inhibidores de serina/treonina cinasa.
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
CO2021010611A2 (es) Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
SV2006002669A (es) Inhibidores de quinasa c-fms ref. prd2368
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
EA202190801A1 (ru) Ингибиторы протеинтирозинфосфатазы